Ellen Weisberg

Ellen Weisberg

UNVERIFIED PROFILE

Are you Ellen Weisberg?   Register this Author

Register author
Ellen Weisberg

Ellen Weisberg

Publications by authors named "Ellen Weisberg"

Are you Ellen Weisberg?   Register this Author

69Publications

1959Reads

43Profile Views

A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk mutation in B-cell malignancies.

Br J Pharmacol 2019 Dec 9;176(23):4491-4509. Epub 2019 Dec 9.

State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, State-Province Joint Engineering Laboratory of Targeted Drugs from Natural Products, School of Life Science, Xiamen University, Xiamen, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bph.14809DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6932946PMC
December 2019

Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological Malignancies.

Biochemistry 2018 02 30;57(5):477-478. Epub 2017 Nov 30.

Department of Medical Oncology, Dana Farber Cancer Institute , Boston, Massachusetts 02215, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.biochem.7b01126DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295915PMC
February 2018

A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader.

Cell Chem Biol 2018 01 9;25(1):88-99.e6. Epub 2017 Nov 9.

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S24519456173038
Publisher Site
http://dx.doi.org/10.1016/j.chembiol.2017.10.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6427047PMC
January 2018

Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7.

Cell Chem Biol 2017 12 19;24(12):1490-1500.e11. Epub 2017 Oct 19.

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.chembiol.2017.09.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5749250PMC
December 2017

Structure-activity relationship investigation for benzonaphthyridinone derivatives as novel potent Bruton's tyrosine kinase (BTK) irreversible inhibitors.

Eur J Med Chem 2017 Sep 9;137:545-557. Epub 2017 Jun 9.

High Magnetic Field Laboratory, Chinese Academy of Sciences, Mailbox 1110, 350 Shushanhu Road, Hefei, Anhui 230031, PR China; CHMFL-HCMTC Target Therapy Joint Laboratory, 350 Shushanhu Road, Hefei Anhui 230031, PR China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejmech.2017.06.016DOI Listing
September 2017

Structure-guided development of covalent TAK1 inhibitors.

Bioorg Med Chem 2017 02 9;25(3):838-846. Epub 2016 Dec 9.

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmc.2016.11.035DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484537PMC
February 2017

Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors.

Bioorg Med Chem 2017 02 7;25(4):1320-1328. Epub 2016 Dec 7.

Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmc.2016.11.034DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5484535PMC
February 2017

Discovery of a Highly Potent and Selective Indenoindolone Type 1 Pan-FLT3 Inhibitor.

ACS Med Chem Lett 2016 May 8;7(5):476-81. Epub 2016 Mar 8.

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, United States; Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, 360 Longwood Avenue, Longwood Center LC-2209, Boston, Massachusetts 02115, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acsmedchemlett.5b00498DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4867484PMC
May 2016

Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia.

Leuk Res 2015 Sep 9. Epub 2015 Sep 9.

Department of Radiation Oncology, Cancer Biology Division, Washington University in Saint Louis School of Medicine, St. Louis, MO, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2015.09.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016250PMC
September 2015

Combination therapy with nilotinib for drug-sensitive and drug-resistant BCR-ABL-positive leukemia and other malignancies.

Arch Toxicol 2014 Dec 21;88(12):2233-42. Epub 2014 Oct 21.

Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00204-014-1385-5DOI Listing
December 2014

The gene dosage of class Ia PI3K dictates the development of PTEN hamartoma tumor syndrome.

Cell Cycle 2013 Dec 15;12(23):3589-93. Epub 2013 Oct 15.

Department of Cancer Biology; Dana-Farber Cancer Institute; Boston, MA USA; Department of Biological Chemistry and Molecular Pharmacology; Harvard Medical School; Boston, MA USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cc.26812DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3903710PMC
December 2013

Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor.

ACS Chem Biol 2013 Oct 13;8(10):2145-50. Epub 2013 Aug 13.

Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School , Charlestown, Massachusetts 02129, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/cb400430tDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3800496PMC
October 2013

Discovery of a selective irreversible BMX inhibitor for prostate cancer.

ACS Chem Biol 2013 Jul 26;8(7):1423-8. Epub 2013 Apr 26.

High Magnetic Field laboratory, Chinese Academy of Sciences , P.O. Box 1110, Hefei, Anhui 230031, P. R. China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/cb4000629DOI Listing
July 2013

Development of 'DFG-out' inhibitors of gatekeeper mutant kinases.

Bioorg Med Chem Lett 2012 Aug 23;22(16):5297-302. Epub 2012 Jun 23.

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2012.06.036DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415686PMC
August 2012

An amino-indazole scaffold with spectrum selective kinase inhibition of FLT3, PDGFRα and kit.

Bioorg Med Chem Lett 2012 Jul 6;22(14):4579-84. Epub 2012 Jun 6.

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2012.05.107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3547541PMC
July 2012

Discovery and characterization of novel mutant FLT3 kinase inhibitors.

Mol Cancer Ther 2010 Sep 31;9(9):2468-77. Epub 2010 Aug 31.

Department of Medical Oncology/Hematologic Neoplasia, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-10-0232DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3967795PMC
September 2010

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.

Nat Med 2010 Apr 14;16(4):483-9. Epub 2010 Mar 14.

[1] Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. [2] Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts, USA. [3] Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm.2112DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3786785PMC
April 2010

FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML.

Drug Resist Updat 2009 Jun 20;12(3):81-9. Epub 2009 May 20.

Department of Medical Oncology/Hematologic Neoplasia, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.drup.2009.04.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4472331PMC
June 2009

Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells.

Mol Cancer Ther 2008 May 29;7(5):1121-9. Epub 2008 Apr 29.

Department of Medical Oncology/Hematologic Neoplasia, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-07-2331DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4034541PMC
May 2008

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.

Nat Rev Cancer 2007 May;7(5):345-56

Dana Farber Cancer Institute, Mayer 540, 44 Binney Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrc2126
Publisher Site
http://dx.doi.org/10.1038/nrc2126DOI Listing
May 2007

Effectiveness of trichostatin A as a potential candidate for anticancer therapy in non-small-cell lung cancer.

Ann Thorac Surg 2006 Mar;81(3):1034-42

Division of Thoracic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.athoracsur.2005.06.059DOI Listing
March 2006

Cloning and functional characterization of the murine mastermind-like 1 (Maml1) gene.

Gene 2004 Mar;328:153-65

Department of Medical Oncology, Mayer 540, Dana-Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gene.2003.12.007DOI Listing
March 2004

Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.

Adv Exp Med Biol 2003 ;532:121-40

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4615-0081-0_11DOI Listing
February 2004

Aminopeptidase inhibitors inhibit proliferation and induce apoptosis of K562 and STI571-resistant K562 cell lines through the MAPK and GSK-3beta pathways.

Leuk Lymphoma 2003 Nov;44(11):1987-96

Department of Internal Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1042819031000122033DOI Listing
November 2003

Resistance to imatinib (Glivec): update on clinical mechanisms.

Drug Resist Updat 2003 Oct;6(5):231-8

Department of Adult Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s1368-7646(03)00062-1DOI Listing
October 2003